We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting (RADAR)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00640406
First Posted: March 21, 2008
Last Update Posted: July 21, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Biotronik AG
  Purpose

The clinical investigation is a prospective, international, multi-centre, randomized (1:1) trial with follow ups at 2, 6, 12 months and 3 years.

The purpose of the study is to evaluate the clinical impact of percutaneous transluminal renal artery stenting (PTRAS) on the impaired renal function measured by the estimated Glomerular Filtration Rate (eGFR) in patients with hemodynamically significant atherosclerotic renal artery stenosis (ARAS).


Condition Intervention Phase
Renal Artery Stenosis Device: Dynamic Renal Stent plus Best Medical Treatment Drug: Best Medical Treatment Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Multi-centre, Prospective Study Comparing Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting in Patients With Hemodynamically Relevant Atherosclerotic Renal Artery Stenosis

Further study details as provided by Biotronik AG:

Primary Outcome Measures:
  • Difference between treatments in change of estimated glomerular filtration rate (eGFR) [ Time Frame: 12 months ]

Enrollment: 86
Study Start Date: April 2008
Study Completion Date: March 2015
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: STN
Device: Dynamic Renal Stent plus Best Medical Treatment
Device: Dynamic Renal Stent plus Best Medical Treatment
percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
Active Comparator: BMT
Drug: Best Medical Treatment
Drug: Best Medical Treatment
best medical treatment for hypertension secondary to renal artery stenosis according to local standards

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Informed consent signed by patient (and/or legal guardian),
  • Hemodynamically relevant de novo unilateral or bilateral atherosclerotic renal artery diameter stenosis RAS (≥ 70%)
  • Estimated GFR > 10 ml/min calculated using the abbreviated Modification of Diet in Renal Disease (MDRD) Study equation,
  • Patients presenting mild, moderate or severe hypertension (defined according to the WHO guidelines) and/or renal dysfunction,
  • Target lesion must be completely coverable by one study stent,
  • Total target lesion length estimated to be less than 19 mm,
  • Target lesion accessible to direct stenting or, after pre-dilation, is likely to sufficiently benefit from stenting (at the discretion of the investigator),
  • Renal reference vessel diameter (RVD) of ≥ 4.0 mm and < 7.0 mm based on visual estimation,
  • Willingness to comply with all the specified follow-up evaluations.

Exclusion Criteria:

  • Estimated GFR ≤ 10 ml/min,
  • Renal atrophy or kidney length < 7cm (referring to kidney with target lesion),
  • Patient not eligible for PTRAS,
  • Patient not eligible for stenting,
  • Target lesion occlusion,
  • Target lesion and/or target vessel proximal to the target lesion is severely calcified,
  • Treatment of branch lesion required,
  • Fresh thrombus or embolic lesion
  • Need for embolic protection in previous or planned PTRAS,
  • Clotting disorders,
  • INR > 2.5 before the intervention,
  • Patient presents fibromuscular dysplasia,
  • Prior revascularization of target lesion,
  • History of target vessel revascularization within the last six months,
  • Angiographic restenosis of any segment of the target vessel that has undergone prior percutaneous intervention,
  • Any thrombolytic therapy procedure within 72 hours prior to planned study procedure
  • Active peptic ulcer or gastro intestinal bleeding,
  • Active inflammation of the kidney interfering with diagnosis and treatment of RAS (e.g. glomerulonephritis, aortitis, vasculitis),
  • Radiation damage of the kidney,
  • Renal disease associated with aortic aneurysm i.e. diameter of the aorta > 40 mm,
  • Chronic renal replacement therapy,
  • Life expectancy < 1 year,
  • Co-morbid conditions limiting participation and follow-up
  • Patient currently participating in another trial possibly influencing the safety of the patient and/or the outcomes of the study,
  • Pregnancy/Planned pregnancy/Childbearing potential without sufficient measures to prevent pregnancy as judged by the investigator,
  • Known allergy to contrast medium that cannot be adequately controlled with pre-medication,
  • Known intolerance against acetylic-salicylic acid (ASA), heparin, clopidogrel and ticlopidin, cobalt-chromium,
  • Metformin intake not stopped at least 48 hours before the intervention
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00640406


Locations
Germany
Herzzentrum Bad Krozingen
Bad Krozingen, Baden-Württemberg, Germany, 79189
Sponsors and Collaborators
Biotronik AG
Investigators
Principal Investigator: Thomas Zeller, PD Dr. med Dep. of Angiology, Herzzentrum Bad Krozingen, Südring 15, 79189 Bad Krozingen, Germany
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Biotronik AG
ClinicalTrials.gov Identifier: NCT00640406     History of Changes
Other Study ID Numbers: C0701
First Submitted: March 17, 2008
First Posted: March 21, 2008
Last Update Posted: July 21, 2015
Last Verified: July 2015

Additional relevant MeSH terms:
Constriction, Pathologic
Renal Artery Obstruction
Pathological Conditions, Anatomical
Kidney Diseases
Urologic Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases